Industry
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Total Trials
4
Recruiting
0
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
Failure Rate
0.0%
0 terminated/withdrawn out of 4 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed trials have results
Key Signals
2 with results
Enrollment Performance
Analytics
Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (4)
Showing 4 of 4 trials
NCT04816604Phase 2Active Not Recruiting
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Role: lead
NCT04456998Phase 2Completed
GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Role: lead
NCT03926793Phase 1Completed
Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension
Role: lead
NCT03473236Phase 1Completed
Phase 1A Safety Trial of Inhaled PK10571 (GB002)
Role: lead
All 4 trials loaded